Your browser doesn't support javascript.
loading
Animal models and animal-free innovations for cardiovascular research: current status and routes to be explored. Consensus document of the ESC Working Group on Myocardial Function and the ESC Working Group on Cellular Biology of the Heart.
van der Velden, Jolanda; Asselbergs, Folkert W; Bakkers, Jeroen; Batkai, Sandor; Bertrand, Luc; Bezzina, Connie R; Bot, Ilze; Brundel, Bianca J J M; Carrier, Lucie; Chamuleau, Steven; Ciccarelli, Michele; Dawson, Dana; Davidson, Sean M; Dendorfer, Andreas; Duncker, Dirk J; Eschenhagen, Thomas; Fabritz, Larissa; Falcão-Pires, Ines; Ferdinandy, Péter; Giacca, Mauro; Girao, Henrique; Gollmann-Tepeköylü, Can; Gyongyosi, Mariann; Guzik, Tomasz J; Hamdani, Nazha; Heymans, Stephane; Hilfiker, Andres; Hilfiker-Kleiner, Denise; Hoekstra, Alfons G; Hulot, Jean-Sébastien; Kuster, Diederik W D; van Laake, Linda W; Lecour, Sandrine; Leiner, Tim; Linke, Wolfgang A; Lumens, Joost; Lutgens, Esther; Madonna, Rosalinda; Maegdefessel, Lars; Mayr, Manuel; van der Meer, Peter; Passier, Robert; Perbellini, Filippo; Perrino, Cinzia; Pesce, Maurizio; Priori, Silvia; Remme, Carol Ann; Rosenhahn, Bodo; Schotten, Ulrich; Schulz, Rainer.
Afiliação
  • van der Velden J; Amsterdam UMC, Vrije Universiteit, Physiology, Amsterdam Cardiovascular Science, Amsterdam, The Netherlands.
  • Asselbergs FW; Netherlands Heart Institute, Utrecht, The Netherlands.
  • Bakkers J; Division Heart & Lungs, Department of Cardiology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
  • Batkai S; Faculty of Population Health Sciences, Institute of Cardiovascular Science and Institute of Health Informatics, University College London, London, UK.
  • Bertrand L; Hubrecht Institute-KNAW and University Medical Centre Utrecht, Utrecht, The Netherlands.
  • Bezzina CR; Hannover Medical School, Institute of Molecular and Translational Therapeutic Strategies, Hannover, Germany.
  • Bot I; Hannover Medical School, Institute of Molecular and Translational Therapeutic Strategies, Hannover, Germany.
  • Brundel BJJM; Université catholique de Louvain, Institut de Recherche Expérimentale et Clinique, Pole of Cardiovascular Research, Brussels, Belgium.
  • Carrier L; Heart Center, Department of Experimental Cardiology, Amsterdam UMC, Location Academic Medical Center, Amsterdam Cardiovascular Sciences, University of Amsterdam, Amsterdam, The Netherlands.
  • Chamuleau S; Division of BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands.
  • Ciccarelli M; Amsterdam UMC, Vrije Universiteit, Physiology, Amsterdam Cardiovascular Science, Amsterdam, The Netherlands.
  • Dawson D; Institute of Experimental Pharmacology and Toxicology, University Medical Center Hamburg Eppendorf, Hamburg, Germany.
  • Davidson SM; DZHK (German Centre for Cardiovascular Research), Partner Site Hamburg/Kiel/Lübeck, Hamburg, Germany.
  • Dendorfer A; Amsterdam UMC, Heart Center, Cardiology, Amsterdam Cardiovascular Science, Amsterdam, The Netherlands.
  • Duncker DJ; Department of Medicine, Surgery and Odontology, University of Salerno, Fisciano (SA), Italy.
  • Eschenhagen T; Department of Cardiology, Aberdeen Cardiovascular and Diabetes Centre, Aberdeen Royal Infirmary and University of Aberdeen, Aberdeen, UK.
  • Fabritz L; The Hatter Cardiovascular Institute, University College London, 67 Chenies Mews, London WC1E 6HX, UK.
  • Falcão-Pires I; Walter-Brendel-Centre of Experimental Medicine, University Hospital, Ludwig-Maximilians-University, Munich, Germany.
  • Ferdinandy P; Division of Experimental Cardiology, Department of Cardiology, Thoraxcenter, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • Giacca M; Institute of Experimental Pharmacology and Toxicology, University Medical Center Hamburg Eppendorf, Hamburg, Germany.
  • Girao H; DZHK (German Centre for Cardiovascular Research), Partner Site Hamburg/Kiel/Lübeck, Hamburg, Germany.
  • Gollmann-Tepeköylü C; DZHK (German Centre for Cardiovascular Research), Partner Site Hamburg/Kiel/Lübeck, Hamburg, Germany.
  • Gyongyosi M; University Center of Cardiovascular Sciences and Department of Cardiology, University Heart Center Hamburg, Germany and Institute of Cardiovascular Sciences, University of Birmingham, UK.
  • Guzik TJ; UnIC - Cardiovascular Research and Development Centre, Department of Surgery and Physiology, Faculty of Medicine, University of Porto, Portugal.
  • Hamdani N; Cardiometabolic Research Group and MTA-SE System Pharmacology Research Group, Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary.
  • Heymans S; Pharmahungary Group, Szeged, Hungary.
  • Hilfiker A; Department of Medicine, Surgery and Health Sciences and Cardiovascular Department, Centre for Translational Cardiology, Azienda Sanitaria Universitaria Integrata Trieste, Trieste, Italy.
  • Hilfiker-Kleiner D; International Center for Genetic Engineering and Biotechnology (ICGEB), Trieste, Italy.
  • Hoekstra AG; King's British Heart Foundation Centre, King's College London, London, UK.
  • Hulot JS; Univ Coimbra, Center for Innovative Biomedicine and Biotechnology, Faculty of Medicine, Coimbra, Portugal.
  • Kuster DWD; Clinical Academic Centre of Coimbra, Coimbra, Portugal.
  • van Laake LW; Department of Cardiac Surgery, Medical University of Innsbruck, Innsbruck, Austria.
  • Lecour S; Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
  • Leiner T; Instutute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
  • Linke WA; Jagiellonian University, Collegium Medicum, Kraków, Poland.
  • Lumens J; Division Cardiology, Molecular and Experimental Cardiology, Ruhr University Bochum, Bochum, Germany.
  • Lutgens E; Institute of Physiology, Ruhr University Bochum, Bochum, Germany.
  • Madonna R; Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre, Maastricht University, Maastricht, The Netherlands.
  • Maegdefessel L; Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.
  • Mayr M; Department for Cardiothoracic, Transplant, and Vascular Surgery, Hannover Medical School, Hannover, Germany.
  • van der Meer P; Department for Cardiology and Angiology, Hannover Medical School, Hannover, Germany.
  • Passier R; Department of Cardiovascular Complications in Pregnancy and in Oncologic Therapies, Comprehensive Cancer Centre, Philipps-Universität Marburg, Germany.
  • Perbellini F; Computational Science Lab, Informatics Institute, Faculty of Science, University of Amsterdam, Amsterdam, the Netherlands.
  • Perrino C; Université de Paris, INSERM, PARCC, F-75015 Paris, France.
  • Pesce M; CIC1418 and DMU CARTE, AP-HP, Hôpital Européen Georges-Pompidou, F-75015 Paris, France.
  • Priori S; Amsterdam UMC, Vrije Universiteit, Physiology, Amsterdam Cardiovascular Science, Amsterdam, The Netherlands.
  • Remme CA; Division Heart & Lungs, Department of Cardiology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
  • Rosenhahn B; Department of Medicine, Hatter Institute for Cardiovascular Research in Africa and Cape Heart Institute, University of Cape Town, Cape Town, South Africa.
  • Schotten U; Department of Radiology, Utrecht University Medical Center, Utrecht, the Netherlands.
  • Schulz R; Institute of Physiology II, University of Muenster, Robert-Koch-Str. 27B, 48149 Muenster, Germany.
Cardiovasc Res ; 118(15): 3016-3051, 2022 12 09.
Article em En | MEDLINE | ID: mdl-34999816
ABSTRACT
Cardiovascular diseases represent a major cause of morbidity and mortality, necessitating research to improve diagnostics, and to discover and test novel preventive and curative therapies, all of which warrant experimental models that recapitulate human disease. The translation of basic science results to clinical practice is a challenging task, in particular for complex conditions such as cardiovascular diseases, which often result from multiple risk factors and comorbidities. This difficulty might lead some individuals to question the value of animal research, citing the translational 'valley of death', which largely reflects the fact that studies in rodents are difficult to translate to humans. This is also influenced by the fact that new, human-derived in vitro models can recapitulate aspects of disease processes. However, it would be a mistake to think that animal models do not represent a vital step in the translational pathway as they do provide important pathophysiological insights into disease mechanisms particularly on an organ and systemic level. While stem cell-derived human models have the potential to become key in testing toxicity and effectiveness of new drugs, we need to be realistic, and carefully validate all new human-like disease models. In this position paper, we highlight recent advances in trying to reduce the number of animals for cardiovascular research ranging from stem cell-derived models to in situ modelling of heart properties, bioinformatic models based on large datasets, and state-of-the-art animal models, which show clinically relevant characteristics observed in patients with a cardiovascular disease. We aim to provide a guide to help researchers in their experimental design to translate bench findings to clinical routine taking the replacement, reduction, and refinement (3R) as a guiding concept.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Animals / Humans Idioma: En Revista: Cardiovasc Res Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Holanda

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Animals / Humans Idioma: En Revista: Cardiovasc Res Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Holanda